Edition:
India

Therapix Biosciences Ltd (TRPX.OQ)

TRPX.OQ on NASDAQ Stock Exchange Capital Market

4.15USD
22 Jun 2018
Change (% chg)

$-0.06 (-1.43%)
Prev Close
$4.21
Open
$4.24
Day's High
$4.24
Day's Low
$4.06
Volume
4,893
Avg. Vol
17,421
52-wk High
$7.67
52-wk Low
$3.84

Chart for

About

Therapix Biosciences Ltd, formerly Nasvax Ltd, is an Israel-based company active in the pharmaceutical sector. The Company develops improved vaccines and immunotherapeutics. Its products include Anti-CD3 oral immunotherapy, directed toward the treatment of inflammatory and autoimmune diseases; Group-common Pneumococcal Vaccine,... (more)
No analyst recommendations are available for .

Overall

Beta: -2.06
Market Cap(Mil.): ₪67.93
Shares Outstanding(Mil.): 138.36
Dividend: --
Yield (%): --

Financials

  TRPX.OQ Industry Sector
P/E (TTM): -- 30.95 32.74
EPS (TTM): -0.19 -- --
ROI: -210.69 14.84 14.38
ROE: -209.27 16.34 16.08

BRIEF-Dual-Listed Therapix To Voluntarily Delist From Tel Aviv Stock Exchange

* DUAL-LISTED THERAPIX TO VOLUNTARILY DELIST FROM TEL AVIV STOCK EXCHANGE

09 May 2018

BRIEF-Therapix Biosciences - Co Terminated Research & License Agreement Between Co, Yissum Research Development Co

* THERAPIX BIOSCIENCES - ON MARCH 18, 2018 CO TERMINATED RESEARCH & LICENSE AGREEMENT BETWEEN CO, YISSUM RESEARCH DEVELOPMENT CO, DATED MARCH 30, 2017 Source text: (https://bit.ly/2F372wh) Further company coverage: (Reuters.Briefs@thomsonreuters.com)

20 Apr 2018

BRIEF-Therapix Biosciences Announces Topline Results Of Phase IIA Study At Yale University For Tourette Syndrome Program

* THERAPIX BIOSCIENCES ANNOUNCES TOPLINE RESULTS OF PHASE IIA STUDY AT YALE UNIVERSITY FOR TOURETTE SYNDROME PROGRAM Source text for Eikon: Further company coverage:

09 Apr 2018

BRIEF-Therapix Biosciences Says U.S. FDA Cleared IND For THX-110 In Treatment Of Chronic Low Back Pain

* THERAPIX BIOSCIENCES - U.S. FDA CLEARED IND FOR THX-110 IN TREATMENT OF CHRONIC LOW BACK PAIN

20 Mar 2018

BRIEF-Therapix Biosciences Expects To Test THX-110 In Early Study In Q2

* THERAPIX BIOSCIENCES LTD - EXPECT TO EVALUATE THX-110 IN A PHASE IIB CLINICAL STUDY IN Q2 OF 2018

07 Feb 2018

BRIEF-Therapix Biosciences Announces Expansion Into Precision Medicine Through New Fully-Owned Subsidiary

* THERAPIX BIOSCIENCES ANNOUNCES EXPANSION INTO PRECISION MEDICINE THROUGH NEW FULLY-OWNED SUBSIDIARY AND PROVIDES CORPORATE UPDATE TODAY AT THE BIOTECH SHOWCASE™ 2018

09 Jan 2018

BRIEF-Therapix Biosciences and Co's CFO Entered Into A "Mutually-Amicable" Separation Agreement

* THERAPIX BIOSCIENCES SAYS CO AND CFO JOSH BLACHER ENTERED INTO A "MUTUALLY-AMICABLE" SEPARATION AGREEMENT ON DECEMBER 19 - SEC FILING

27 Dec 2017

Earnings vs. Estimates